ARTICLE | Management Tracks
New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose
February 13, 2021 2:55 AM UTC
SR One named Chris Chai and Peter Van Vlasselaer venture partners. Chai was CFO of Principia Biopharma Inc., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired last year for $3.4 billion. Van Vlasselaer was most recently founder, president, and CEO of ARMO Biosciences Inc.; Eli Lilly and Co. (NYSE:LLY) acquired that biotech for $1.6 billion in 2018. After a long history as the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), SR One was spun out last year.
Surface Oncology Inc. (NASDAQ:SURF) promoted Robert Ross from CMO to president and CEO, effective April 1. Ross succeeds Jeff Goater, who will become chairman. Current chairman Daniel Lynch will become a senior adviser to the antibody company. ...